Also, we should mention that VRTX has a PEG ratio of 2.11. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. VRTX's indu
We also can’t discuss CRSP stock without also talking about Vertex Pharmaceuticals (Nasdaq: VRTX). CRISPR and Vertex Pharmaceuticals (Nasdaq: VRTX) Vertex Pharmaceuticals owns 60% of CRISPR’s gene editing therapy for CASGEVY. Right now, CASGEVY is in a bit of an exploratory phase. It has ...
In October 2024, NTLA announced positive data from the ongoing phase I/II study of NTLA-2002 in HAE patients. These data, however, didn’t seem to impress investors and the stock was hit hard following the announcement. The FDA approval of Vertex andCRISPR Therapeutics’CRSPCRISPR/Cas9 genome...